DOTAP VEGF-A siRNA containing an immunostimulatory motif significantly increased anti tumoral therapy efficacy in an HCC orthotopic fibrotic tumor model
M Kornek, V Lukacs-Kornek, E Raskopf, U Becker, M Klöckner, T Sauerbruch, V Schmitz · Zeitschrift für Gastroenterologie · 2008 · Heft 01
Bibliografische Angaben
Zusammenfassung
BACKGROUND/AIMS Most experimental therapy studies are performed in mice that bear subcutaneous or orthotopic hepatoma but are otherwise healthy and non-fibrotic. However, the majority of hepatocellular carcinoma develops in patients suffering from pre-existing liver fibrosis. Here we investigated the efficacy of a standard experimental therapeutic approach to interrupt the VEGF/VEGFR cascade via VEGF-A silencing in pre-fibrotic HCC mice with or without DOTAP (cationic lipid) formulation. RESULTS We could show that the treatment with naked VEGF-A siRNA (200µg/kg) was inefficient to treat HCC under this pre-fibrot…
